Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 2/20 | 0.49 |
| ▸ | ATP4B | P51164 | 2/20 | 0.49 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22824711 | 0.87 | MAPT (0.45) | SREBF2RAB9AALDH1A1MAPTNPC1 | |
| SCHEMBL2609421 | 0.84 | RAB9A (0.53) | SREBF2RAB9AALDH1A1MAPTNPC1 | |
| SCHEMBL2513271 | 0.82 | RAB9A (0.58) | ATP4AATP4BSREBF2RAB9AALDH1A1 | |
| SCHEMBL12297331 | 0.82 | RAB9A (0.56) | SREBF2RAB9AALDH1A1MAPTNPC1 | |
| SCHEMBL10052165 | 0.82 | KMT2A (0.58) | SREBF2RAB9AALDH1A1MAPTNPC1 | |
| SCHEMBL2609415 | 0.82 | RAB9A (0.56) | SREBF2RAB9AALDH1A1MAPTNPC1 | |
| SCHEMBL2754043 | 0.81 | ALDH1A1 (0.55) | ATP4AATP4BSREBF2RAB9AALDH1A1 | |
| SCHEMBL14558317 | 0.81 | RAB9A (0.50) | RAB9AMAPTNPC1SMN1; SMN2POLB | |
| SCHEMBL5647658 | 0.81 | KMT2A (0.49) | ATP4AATP4BSREBF2RAB9AALDH1A1 | |
| SCHEMBL27633290 | 0.80 | RAB9A (0.44) | ATP4AATP4BSREBF2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174949-B2 | Hedgehog inhibitors | SELEXAGEN THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174949-B2 | Hedgehog inhibitors | SELEXAGEN THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174949-B2 | Hedgehog inhibitors | SELEXAGEN THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130012513-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20130012513-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20130012513-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. | 2013-01-10 | — | — | US | disclosed |
| EP-2521451-A1 | HEDGEHOG INHIBITORS | Selexagen Therapeutics, Inc. (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | disclosed |
| EP-2394993-A2 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2011-12-14 | — | — | EP | disclosed |
| WO-2011085128-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | NOS3, PTMS, NOS2 | ATP4A 1369/4885ATP4B 1038/4885SREBF2 549/4885 |
| US-20130012513-A1 | HEDGEHOG INHIBITORS | SHH, SMO, GLI1 | ATP4A 4309/4885ATP4B 4063/4885SREBF2 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.